NCT07428031Not yet recruiting
French Registry: Late Gadolinium Enhancement in Hypertrophic Cardiomyopathy
Retrospective French Registry of Cardiovascular Magnetic Resonance Late Gadolinium Enhancement in Patients With Hypertrophic Cardiomyopathy
Source: ClinicalTrials.gov · Last updated 23 Feb 2026
Brief summary (registry, in English)
This study aims to create a registry of patients with hypertrophic cardiomyopathy, a condition characterized by excessive thickening of the heart muscle. This disease can sometimes lead to serious complications. Currently, the prognosis of these patients is mainly determined by clinical and echocardiographic parameters. Detection of myocardial fibrosis using cardiac MRI enables better risk stratification for these patients.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 5000 (estimated)
- First submitted
- 16 Feb 2026
- Start date
- 1 Mar 2026
- Primary completion date
- 1 Mar 2031
- Lead sponsor
- Assistance Publique - Hôpitaux de Paris
- Diseases
- Hypertrophic cardiomyopathy
- NCT number
- NCT07428031
What you commit to
- Study type: Observational
- Planned participants: 5000
- From 1 Mar 2026 to the primary completion date, 1 Mar 2031
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Patients with a history of ischemic cardiomyopathy or myocarditis.
Other
- Patients unable to provide informed consent,
Who the study is looking for
- Age ≥ 18 years
- Ability to provide informed consent
- HCM diagnosis referred for CMR assessment.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.